Adding the new calcium antagonist mibefradil to patients receiving long-term beta-blocker therapy results in improved antianginal and antiischemic efficacy.

Schneeweiss, A; Kobrin, I; Charlon, V; Caspi, A; Marmor, A; Sclarovsky, S; Reisin, L; Schlesinger, Z

Schneeweiss, A; Kobrin, I; Charlon, V; Caspi, A; Marmor, A; Sclarovsky, S; Reisin, L; Schlesinger, Z.

Affiliation

Schneeweiss A; Cardiovascular Research Foundation, Tel Aviv, Israel.

Am Heart J ; 135(2 Pt 1): 272-80, 1998 Feb.

Article in En | MEDLINE | ID: mdl-9489976

Subject(s)

Adrenergic beta-Antagonists/therapeutic use; Angina Pectoris/drug therapy; Benzimidazoles/therapeutic use; Calcium Channel Blockers/therapeutic use; Tetrahydronaphthalenes/therapeutic use; Adrenergic beta-Antagonists/administration & dosage; Benzimidazoles/administration & dosage; Benzimidazoles/adverse effects; Calcium Channel Blockers/administration & dosage; Calcium Channel Blockers/adverse effects; Double-Blind Method; Drug Therapy, Combination; Exercise Test; Female; Humans; Male; Mibefradil; Middle Aged; Tetrahydronaphthalenes/administration & dosage; Tetrahydronaphthalenes/adverse effects; Time Factors

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Tetrahydronaphthalenes / Benzimidazoles / Calcium Channel Blockers / Adrenergic beta-Antagonists / Angina Pectoris Type of study: Clinical_trials Limits: Female / Humans / Male / Middle aged Language: En Journal: Am Heart J Year: 1998 Document type: Article

Search on Google

XML

PubMed Links